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Autoimmune diseases are caused at least in part by autoantibody-mediated immune 
responses. Several studies have reported altered risks for developing cancer in patients 
with autoimmune diseases. In breast cancer patients, the appearance of autoantibodies is 
temporally associated with the onset of malignant disease (Shah et al., 2010). However, 
the function of these autoantibodies in tumor progression remains unclear. Recent work 
from our laboratory shows that breast cancer invasion is led by specialized cancer cells 
that express cytokeratin-14 (K14). Interestingly, preliminary data from the Rosen 
laboratory detected autoantibodies against K14 in the serum of patients with autoimmune 
disease. Based on these data, we raised the specific hypothesis that autoantibodies directly 
limit tumor progression and metastatic spread by binding to tumor antigens on invasive 
cancer cells. We show here that purified IgGs from the sera of lupus, dermatomyositis and 
scleroderma patients bind human mammary tumor antigens and some of these 
autoantibodies (13200, 12106, and SLE1269) reduce tumor invasion in a 3D organotypic 
culture system. Furthermore, autoantibodies from patients with no cancer are more 
effective at blocking tumor invasion when compared to corresponding antibodies from 
cancer patients. The work described in this thesis presents the first experimental evidence 
implicating therapeutic roles of patient-derived autoantibodies in blocking breast tumor 
invasion. Additionally, targets of these antibodies may provide lead candidates for 
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CHAPTER 1: INTRODUCTION 
1.1 Autoimmune Diseases  
An autoimmune disease is a clinical syndrome in which an active immune response by T 
cells and/or B cells affects one’s self-tissues. With the exception of rheumatoid arthritis, 
most of these diseases are rare and affect only 5% of the population of the western 
countries (Sinha et al., 1990).  
1.1.a. Autoimmunity 
Despite some progress, autoimmune diseases remain a challenging field to study and 
their precise causes remain poorly understood. For several years, immunology was 
founded on the principle that our immune cells (mainly T and B cells) recognize only 
foreign antigens and remain inactive towards self-tissues (Kyewski and Klein, 2006). In 
line with this, during lymphocyte development, genes encoding antigen receptors are 
randomly rearranged and the lymphocyte is exposed to antigenic signals from self-tissues. 
Immune cells that exhibit weak interactions with self-antigens are considered stimulatory 
and suitable for mounting immune responses against foreign pathogens, a process called 
positive selection (Kyewski and Klein, 2006). On the other hand, negative selection 
induces programmed cell death in immune cells that display high-affinity interactions 
with self-antigens (Kyewski and Klein, 2006). However, we now acknowledge that this 
process of negative selection is ‘leaky’ and some T cells with a high affinity for self-
antigens can escape deletion and migrate to the periphery (Danke et al., 2004). At the 
periphery, there are several cell-intrinsic or cell-extrinsic regulatory mechanisms that 
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prevent activation of these escapees. Some of these mechanisms include induction of 
anergy, production of down-regulatory cytokines by regulatory T cells or interference 
with receptor signaling pathways (Seddon and Mason, 2000). Since this escape occurs 
physiologically in normal individuals, it is challenging to understand how this process 
becomes pathologic resulting in autoimmune disorders. 
 
Fig 1: Schematic describing cell fate of a T cell that escape negative selection. 
Hematopoietic precursor cells undergo positive or negative selection based on their 
interactions with self-antigens. Fraction of self-reactive T cells escape negative selection 
and are controlled by peripheral tolerance mechanisms which could be T-cell intrinsic or 
T-cell extrinsic. (Walker and Abbas, 2002) 
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 1.1.b Autoantibodies in Normal Physiology and Pathobiology 
The immune system of healthy individuals also contains self-reactive T and B cells (Filion 
et al., 1996). Antibodies circulating in the serum of normal individuals, in the absence of 
any known immunization with the target antigen, are called natural autoantibodies. 
Natural antibodies consist of predominantly IgM, IgG and IgA immunoglobulins encoded 
by germline genes that exhibit a low-affinity for self-antigens (Tomer and Shoenfeld, 
1988). Some of these antigens include nuclear proteins, DNA, cytoskeletal proteins, 
intracellular and membrane proteins (Coutinho et al., 1995). In contrast to the antigen‐
specific antibodies that are secreted by mature B cells in a T‐cell dependent pathway in 
response to a foreign pathogen (Muramatsu et al., 1999), natural antibodies are not antigen 
specific towards pathogens and are produced by innate‐like B cells in a T‐cell independent 
manner (Avrameas, 1991). It has been estimated that 5-15% of splenic B cells secrete 
natural autoantibodies.  These antibodies are believed to be conserved through evolution, 
suggesting that they are important in normal physiology for maintaining tissue 
homeostasis (Coutinho et al., 1995). Major functions of these autoantibodies involve 
scavenging for metabolic waste and senescent cells (Grabar, 1975), protection against viral 
and bacterial infections (Ochsenbein et al., 1999), and control of autoimmune diseases 
(Cohen and Cooke, 1986). Owing to its flexible antigen binding domain and pentameric 
structure, natural IgMs bind non‐specifically to a wide range of microbes and activate the 
complement cascade (Ehrenstein and Notley, 2010). 
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There are several autoantigens including DNA and myelin proteins that are recognized 
by natural autoantibodies and are also targeted during the progression of autoimmune 
diseases like lupus (Cohen, 2000). Thus, it could be imagined that autoimmune disorders 
arise simply due to the deregulation of natural autoantibodies (Lacroix-Desmazes et al., 
1998).  
 1.1.c Causes of Autoimmune Diseases 
The etiology and pathogenesis of autoimmune diseases remains largely unknown. 
Genetic factors are considered to be a crucial determinant of susceptibility to autoimmune 
disorders (Invernizzi, 2007) where there seems to a familial clustering in patients. 
Furthermore, the rate of autoimmune disease concordance is at least four times or higher 
in monozygotic twins than in dizygotic twins (Cooper et al., 1999). Like most other 
diseases, autoimmune diseases are multigenic, that is, development of autoimmunity in 
patients occurs when multiple genes work together to produce an abnormal phenotype 
(Encinas and Kuchroo, 2000). Even in a genetically predisposed person, some form of 
external trigger — either in the form of an environmental exposure or a change in the 
internal environment — is usually required to stimulate an autoimmune response. The 
importance of these environmental triggers can be seen in studies of genetically similar 
populations in different environments. For instance, the incidence of type I diabetes and 
multiple sclerosis in a specific population is altered significantly as individuals migrate to 




 1.1.d. Examples of Autoimmune Diseases 
Dermatomyositis 
Inflammatory myositis, which refers to the inflammation of muscle, is used to describe 
dermatomyositis, polymyositis, necrotizing myopathy, and inclusion-body myositis. 
Dermatomyositis affects 5 in every 100,000 persons in the United States (Furst et al., 2012). 
Common symptoms include a characteristic rash and muscle weakness which developed 
within a few weeks. The pathology of the disease includes binding of immune complexes 
to endothelial cells, activation of the complement system and subsequent lysis, leading to 
a decreased number of capillaries in the muscle (Mammen, 2010). Autoantibodies 
preferentially associated with dermatomyositis include those recognizing Mi-2, MDA5, 
TIF1γ, and NXP-2 – each associated with a distinct phenotype (Shah et al., 2015). 
Scleroderma 
Scleroderma is a systemic autoimmune disease best characterized by the hardening of the 
skin due to the increased synthesis of collagen leading to abnormal connective tissue 
(Fleming and Schwartz, 2008). The overall incidence rate of scleroderma in the adult 
population of the United States is approximately 20 per million per year (Mayes et al., 
2003). Most patients affected by the disease present with Raynaud’s phenomenon – 
reduced blood flow resulting in discoloration of fingers and toes. The most common 
scleroderma-specific autoantibodies include anticentromere, anti-topoisomerase, and 




Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease that 
affects joints, skin, lungs, kidneys, blood cells or heart and follows a relapsing and 
remitting course. The disease is characterized by a multisystem inflammation with the 
generation of autoantibodies including antinuclear, anti-ds DNA, anti-ribonucleoprotein, 
anti-Ro, and anti-La (Ippolito et al., 2011). The incidence of lupus is about 5-7 per 100,000 
persons (Somers et al., 2014).  Symptoms for the disease may vary between individuals, 
but usually include chest pain, fatigue, hair loss, mouth sores, fever with no cause, and/or 
a butterfly rash.  
 
Fig 2: Characteristic rashes of dermatomyositis, scleroderma, and lupus (butterfly rash). 







1.2 Breast cancer 
Breast cancer refers collectively to neoplasms arising from the tissue of the breast. Breast 
cancers are often an adenocarcinoma, which is a cancer of the gland tissues (Allison, 2012).  
Types of breast cancer include: 
 Ductal carcinoma in-situ (DCIS): Cancer begins in cells lining the ducts, 
but these cells do not invade through the walls of the breast. 
 Invasive ductal carcinoma (IDC): Most common type of breast cancer that 
begins with cells lining the duct, which then invade into the surrounding 
breast tissue.  
 Invasive lobular carcinoma: This cancer starts with the cells lining the 
lobules and can spread to nearby lymph nodes or other parts of the body.   
 Inflammatory breast cancer: Cancer cells in this rare subtype block lymph 
vessels in the skin which causes symptoms similar to those that may occur 
during inflammation.  
1.2.a Occurrence, Progression and Patient Outcome 
Breast cancer is the most common cancer in women in the United States and the leading 
cause of death in these women (United States Cancer Statistics: 1999–2011 Incidence and 
Mortality Web-based Report). Although breast cancer can occur at any age, it is more 
likely after age 40, and the risk increases with age. The number of breast cancer cases 
diagnosed every year is the highest among all cancers and accounts for about 12% of all 
new cancer cases, and 25% of all the cancers in women (Jemal et al., 2010). One in every 
 
8 
eight (12%) women in the United States run the risk of being diagnosed with invasive 
breast cancer during her lifetime. It is estimated that 243,190 new cases of breast cancer 
will be diagnosed in 2015, and more than 40,000 of these women will succumb to their 
disease. In 2014, there were more than 2.8 million women with a history of breast cancer 
in the U.S (American Cancer Society, Surveillance Research, 2014). 
 
Fig 3: Heat map describing breast cancer incidence per 100,000 individuals, 2008. 
 (Source: http://chartsbin.com/view/yq6) 
 
Breast cancer is a heterogeneous disease that develops in a continuum. The normal breast 
terminal end bud consists of lobules and ducts organized as a bi-layered epithelium of 
luminal and myoepithelial cells (Vargo-Gogola and Rosen, 2007). Atypical hyperplasia 
(ADH) is a pre-malignant lesion with abnormal cell layers in the duct or lobule. This 
progresses into DCIS which is characterized by abnormal cells. These cancer cells can then 
invade past the basement membrane in IDC, and once this happens the risk for 
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developing secondary tumors or metastases (MET) increases significantly (Vargo-Gogola 
and Rosen, 2007).  
 
Fig 4: Breast cancer pathogenesis and progression. The normal breast epithelium consists 
of a bi-layered epithelium composed of luminal and myoepithelial cells arranges as 
lobules and ducts. Order of premalignant to malignant disease – ADH, DCIS, and IDC. 
Once cancer cells have escaped past the basement membrane in IDC, they can enter the 
vasculature and seed a secondary tumor at a foreign microenvironment. Progression to 
metastatic disease could occur due to combinations of genetic, epigenetic and 
environmental alterations (Vargo-Gogola and Rosen, 2007). 
 
10 
1.2.b Breast Cancer Treatment: Cancer immunotherapy 
The overall 5-year survival rate for breast cancer has seen a dramatic improvement from 
63% in the 1960s to 90% now (Berry et al., 2005). Patients with local, non-invasive disease 
have a very promising survival rate of 98%. Treatment options for breast cancer patients 
include surgery (lumpectomy – resection of the tumor and surrounding breast tissue, 
mastectomy – removal of entire breast, axillary lymph node dissection – removal of lymph 
nodes draining the breast), radiation therapy, hormone therapy, or chemotherapy (1998). 
The modern treatment of breast cancer has evolved to include targeted approaches, with 
treatment based on the presence or absence of receptors for estrogen (ER), progesterone 
(PR), and HER2 (Tinoco et al., 2013). Almost 75% of breast cancers are ER-positive and 
majority of these malignancies respond to treatments that reduce circulating estrogens. 
Tamoxifen, an antiestrogen, completely binds the ER and inhibits estrogen binding 
(Miller, 2004).  
An important principle in cancer immunotherapy is that the emergence of cancer 
represents a failure of the body to mount an effective immune response against cancer 
(Parish, 2003). Passive cancer immunotherapy uses antibodies to target specific antigens 
in the cancer: for example, the breast cancer drug Herceptin is an antibody that targets the 
HER2 receptor. Binding of the drug to the HER2 receptor on the surface of breast tumor 
cells prevents cell growth (Mathe, 1987). However, drugs against cancer proteins within 
cells have not been developed because antibodies are considered too large to pass through 
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the membrane of most cell types. Yet, evidence for antibodies having the potential to enter 
viable cells has been accumulating since 1978 (Alarcon-Segovia et al., 1978). 
1.2.c  Collective Cell Invasion and Metastasis 
The spread of cancers, from their organs of origin to other sites within the body, a process 
called metastasis, constitutes a defining hallmark of malignancy (Hanahan and Weinberg, 
2011). It continues to be the most difficult clinical problem complicating the treatment of 
cancer patients. About 20-50% of patients diagnosed with breast cancer eventually 
progress to metastatic disease (Lu et al., 2009). Despite advances in the treatment of early 
stage breast cancer, mortality from metastatic breast cancer has remained unchanged over 
the last 30 years (Tevaarwerk et al., 2013).  The 5-year survival rate for localized disease is 
98%, but the number falls to 22% for patients with distant metastasis (Cancer Research, 
UK). Thus, there remains a critical need for both an understanding of the mechanisms 
underlying metastasis and the development of therapeutic approaches to target the 
metastatic process.  
Metastasis is a multi-step process that begins with cancer cell motility, invasion, 
dissemination, intravasation into a blood or lymphatic vessel, extravasation and 
colonization at a distant site (Chaffer and Weinberg, 2011). Only a very small set of tumor 
cells succeed at each of these steps, making metastasis a very inefficient process (Sahai, 
2007). The acquisition of an invasive phenotype by tumor cells is one of the first steps of 
the process. Traditionally, invasion is defined as the penetration of healthy tissue by either 
single cells, groups of cells or strands of connected tumor cells (Leighton et al., 1960). For 
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breast cancer, the tumor border is commonly surrounded by a collective and invasive 
group of cells that express cell adhesion molecules like cadherins (Friedl et al., 2012). The 
morphology and organization of collectively invading cancer cells can vary considerably 
- ranging from strands of only one or two cells in diameter, to broad masses that can 
include cells that do not contact the extra-cellular matrix (ECM). It is believed that this 
collective cell behavior is likely to contribute to several steps of the metastatic cascade 
(Friedl et al., 2012).  
 
Fig 5: Collective invasion in a clinical tumor specimen. Cells within the tumor mass are 
interconnected (white lines), and smaller collective groups of cells have invaded into the 
surrounding stroma (direction of invasion marked by black arrows). (Friedl et al., 2012) 
  1.2.d Modelling breast tumor behavior in 3D organotypic culture systems 
The inaccessibility of the relevant anatomical sites has hindered our ability to study 
metastasis. Despite that, we have made significant progress by developing three-
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dimensional (3D) culture systems and advanced molecular tools that allow us to study 
mammalian biology in real-time. 
Two-dimensional culture enabled biologists to observe and manipulate mammalian cells 
and laid the foundation for cell and molecular biology. However, these culture systems 
fail to emulate the three-dimensional (3D) architecture and organization of the tissue in 
relation to its surrounding microenvironment. Consequently, there is an incomplete 
understanding of mammalian biology at the tissue level (Shamir and Ewald, 2014). To 
overcome this barrier, we developed an ex-vivo organotypic culture system that allows 
us to study the epithelial biology of the mammary gland in an environment that closely 
resembles that in vivo (Simian et al., 2001). Organoids containing several hundred cells 
isolated from primary tissue are capable of reorganizing into their normal spatial 
configuration as observed in vivo when embedded in 3D ECM gels (Matrigel or Collagen). 
The choice of the microenviroment can dictate cell behavior of organoids (Nguyen-Ngoc 
et al., 2012). When normal mammary organoids are embedded in a basement membrane 
rich ECM (Matrigel), organoids undergo branching morphogenesis. While in collagen I, 
the same organoids exhibit robust transient migration and dissemination (Nguyen-Ngoc 




Fig 6: The microenvironment regulates epithelial behavior. Organoids generated from 
the same mammary tissue (normal gland or tumor) show altered invasive and 
disseminative behaviors when exposed to different microenvironments – Matrigel or 
Collagen I. (Shamir and Ewald, 2014) 
Collective cancer cell invasion can be observed in similar 3D matrix-based organotypic 
cell cultures. In such ex-vivo cultures, collective invasion observed in vivo could be 
correlated to migration of multicellular groups of cells within organoids while retaining 
their cadherin based cell junctions (Ewald et al., 2008). In the Ewald lab, we mechanically 
and enzymatically digested mammary tumors from mice to generate clusters of 100-300 
tumor cells called organoids. To study collective invasion, we embed these organoids into 
a collagen I gel that closely resembles the tumor microenvironment of an invasive breast 
carcinoma. After 48-72 hours, organoids progressively extend multicellular strands into 
the collagen I.  Our research group has previously identified specialized cancer cells that 
commonly lead collective invasion in breast cancers (Cheung et al., 2013). The cells leading 
these invasive stands or leader cells express basal epithelial genes including keratin-14 
(K14). Luminal cancer cells convert phenotypically into these leader cells upon induction 
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of K14 expression. Importantly, a knockdown of K14 was sufficient to block collective 
invasion in culture and in vivo (Cheung et al., 2013). 
 
Fig 7: Collective invasion is led by K14+ cells. Organoids generated from mammary 
tumors of a mouse model of breast cancer collectively invade into collagen I gels. These 
invasive strands are led by K14+ cells. K14 expression is required for efficient metastasis 










1.3 Autoimmunity and Cancer 
1.3.a. Cancer Immunosurveillance and Immunoediting 
It was proposed as early as the 1950s that mutations in cancer might provoke the immune 
system to mount a response, causing tumor regression (Burnet, 1957). However, this 
hypothesis faded after numerous experiments in immunocompromised mice failed to 
show an increase in cancer development when exposed to a mutagen (Stutman, 1975). 
However, in the last few decades we now recognize the importance of the immune system 
is controlling cancer. Natural killer cells and T-cells are essential components of this 
process and recognize ‘stress’ and ‘danger’ signals presented by tumor cells (Diefenbach 
and Raulet, 2002).  Instead, we now recognize that several components of the immune 
system such as IFN gamma and perforin, are required for regulating cancer initiation 
(Street et al., 2001). The immune system is effective in recognizing certain tumor antigens, 
making the tumor immunologically active.  
Tumors are constantly modulated by the immune system such that the resulting tumor is 
less capable of stimulating a host immune response, a process called immunoediting 
(Dunn et al., 2002). Common forms of immunoediting include loss of expression of tumor 
antigens by the tumor cells to avoid immune detection, or expression of immune 
checkpoints by the cancer (Pardoll, 2012). 
Based on the relative dominance of the cancer or the immune response, cancer 
immunoediting has three stages – elimination, equilibrium, and escape (Schreiber et al., 
2011). During the elimination stage, the immune system dominates and cancer is 
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eliminated. In the equilibrium stage, the cancer and the immune responses are balanced 
such that neither does the cancer advance significantly, nor does the immune system beat 
the cancer. The third stage of escape represents the unregulated cancer growth (Screiber, 
2011). 
1.3.b Association of Autoimmune Diseases and Cancer 
Connections between autoimmune rheumatic diseases and cancer have been becoming 
increasingly evident over the last few decades. Although a clear cause for autoimmune 
diseases has not been identified, it is believed that the dynamic interactions between 
cancer and the immune system may be relevant to understanding the origins of 
autoimmunity (Schreiber et al., 2011). These interactions are bidirectional; the success of 
immune checkpoint inhibitors as potent anti-cancer therapies, suggest that natural 
immune responses to cancer occur and could regulate the emergence of cancer. 
In some cases, autoimmune antibodies may be produced as a result of an autoantigen 
mutation in the patient’s cancer. In a subset of scleroderma patients with RNA Polymerase 
III (RNAPol III) autoantibodies, malignancy was detected in a close temporal association 
with the clinical onset of autoimmune disease (Joseph et al., 2014). Tumors from these 
patients had genetic alterations in the gene encoding RNAPol III. In contrast, patients with 
autoantibodies against other antigens did not have mutations in the RNA Pol III gene. 
This data suggests that expression of RNAPol III autoantibodies in cancers might be 
specific to scleroderma immune responses (Joseph et al., 2014). Although this immune 
response against RNAPol III was initiated against the mutated protein, the immune 
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response spreads to the wild type version, causing injury to self-tissues. Perhaps, in RNA 
polymerase III-positive scleroderma patients with no detectable cancer (~80% of 
scleroderma patients), the immune system successfully eradicated any cancer that may 
have arisen (Joseph et al., 2014). This idea strongly implicates the importance of the 
immune system in maintaining cancers in the elimination stage and forms the basis for 
the hypothesis of this thesis work.  
Similar studies in patients with dermatomyositis suggest that patients with a malignancy 
have cancer up to 2 years prior to myositis diagnosis (Hill et al., 2001). Patients with 
myositis-specific autoantibodies have a significantly lower risk of an associated cancer 
compared to autoantibody negative myositis patients (Chinoy et al., 2007). Recent reports 
indicate that cancer therapy may improve outcomes in myositis, implicating a mechanistic 
relationship between cancer and the autoimmune disease. Unfortunately, investigating 
the temporal association between cancer and autoimmune diseases is complicated 
because of the variations in clinical phenotypes, tumor types, age of onset of autoimmune 
disease, cancer and rheumatic therapies used on the patient.  
1.3.c. Model for cancer-induced autoimmunity 
Transformation of normal cells could occasionally result in the mutation of existing 
autoantigens. These mutations are secondary mutations in a subset of cells, and thus, not 
all cancer cells will have them. The first immune response would be mounted against this 
mutated form of the antigen, and may eventually spread to the wild-type version due to 
epitope spreading. During this process, auto-reactive T cells become activated in response 
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to self-epitopes released due to tumor-specific T cell-mediated damage. Immune cells are 
now capable of destroying cancer cells with the mutation, and also cancer and other 
normal self-tissues that express the wild type antigen. Once initiated, this autoimmune 
response is self-propagating, and results in significant tissue damage (Shah et al., 2015). 
In patients with autoimmune diseases that do not present with a malignancy, the immune 
system could be hypothesized to have successfully eradicated the cancer.  
 
Fig 8: A model for cancer-induced autoimmunity. Transformation of normal cells could 
mutate autoantigens. Immune response initially targets cancer cells with these mutations 
but eventually spreads to those with the wild-type version as well. Effector cells targeting 
with wild-type alleles also cross-react with healthy tissues, resulting in autoimmune 
disease. (Shah et al., 2015) 
1.3.d. Autoantibodies and Cancer 
Autoantibodies are commonly detected in the serum of cancer patients. For 
example, antibodies against p53 and p16 were detected in 10–20 % of patients with 
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various types of cancers (Soussi, 2000). The identification of circulating biomarkers of 
early stage malignancy is a critical component of ongoing efforts aimed at reducing the 
overall burden of human cancer through early detection.  
Antibodies are a critical part of our immune response against foreign antigens. Antibody 
dependent cellular cytotoxicity is a mechanism by which effector cells of the immune 
system lyse a target cell with antibodies bound to its membrane antigens. Antibodies 
bound on the cell surface of a pathogen also activates the complement system and causes 
subsequent pathogen destruction (Seidel et al., 2013). It was reported in 1978 that an 
autoantibody to nuclear ribonucleoprotein from the serum of a lupus patient penetrates 
the nuclei of live human mononuclear cells through Fc receptors (Alarcon-Segovia et al., 
1978). Such penetrated autoantibodies can have varied effects on the cell expressing the 
antigen ranging from no effect, induction of apoptosis, or mitotic arrest (Alarcon-Segovia, 
2001). It was recently shown that a cell-penetrating lupus antibody, 3E10, inhibits DNA 
repair, and as a single agent is lethal to BRCA-2 deficient human cancer cells (Hansen et 
al., 2012). Although patients with lupus are at an increased risk for developing cancer, 
they have a lower incidence of breast and ovarian cancers compared to control 
populations (Bernatsky et al., 2011). Based on this, it could be hypothesized that 
circulating autoantibodies in lupus patients provides protection against the development 





1.4 Hypothesis and Rationale for Thesis: 
The cause of autoimmune diseases is still widely debated in the scientific community. 
Recent evidence suggests that a malignancy can drive the emergence of certain 
autoimmune diseases in patients. Cancer and autoimmune disease is diagnosed around 
the same time point in scleroderma patients with POLRA3 autoantibodies in their serum 
(Joseph et al., 2014). It is believed that the immune system is very active during the initial 
stages of cancer, and can succeed in keeping the cancer at bay. This is expected to be the 
case in patients with scleroderma and RNA Pol III autoantibodies where a malignancy 
doesn’t develop.  
The laboratory of Dr. Antony Rosen has identified autoantibodies against K14, a protein 
we have shown to be important for collective invasion in breast cancer, in patients with 
dermatomyositis. There are several recent reports that suggest malignancy is identified in 
patients with dermatomyositis prior to the clinical onset of the autoimmune disease (Hill 
et al., 2001). Thus, autoantibodies generated in these patients could represent the 
involvement of the immune system in fighting the cancer by developing antibodies 
against an antigen critical to tumor progression (K14).  
Based on these preliminary studies, we initiated a collaboration with Dr. Antony Rosen 
to study the function of autoimmune antibodies in regulating collective cancer invasion. 
The aim of this thesis project is to evaluate the role patient derived autoantibodies in 




CHAPTER 2: MATERIALS AND METHODS 
Purification of Autoantibodies from Human Serum 
Blood was collected from healthy controls or patients with autoimmune diseases 
(dermatomyositis, lupus, or scleroderma). To avoid the dilution of serum samples, zebra 
spin desalting columns (89882; Life Technologies) were used to perform buffer exchange 
into sodium phosphate for the subsequent steps. For purifying the total IgG from the 
serum, the flow through was collected from running the sample through Melon gel IgG 
spin purification kits (45206; Life technologies).  The IgG concentrations of the sample was 
then estimated by coomassie staining of samples that were electrophoresed on SDS-PAGE 
gels. For estimating the standard curve, rabbit IgG samples of 5, 10, 20, 40 and 80ug were 
run on each of these gels.  Purified IgGs were then stored at –80⁰C. 
Isolating Human Tumor Organoids 
Using mechanical disruption, enzyme digestion, and centrifugation we purified 
fragments of primary mammary tumors called tumor organoids. Human tumors arrive 
from the Cooperative Human Tissue Network (CHTN) in DMEM. The media is washed 
out, tumors are then treated very briefly with 5mL of fungizone solution: 10ml Pen-Strep 
(P4333; Sigma), 10ml Fungizone (15290-018; Life Technologies), and 500 ml DPBS (D8662; 
Sigma). Primary breast tumors from patients with metastatic disease were minced with a 
scalpel and digested for 1  hour at 37°C in collagenase solution: (DMEM (10565–018; 
Gibco) with 2 mg/ml collagenase (C2139; Sigma-Aldrich), 5% FBS (F0926; Sigma-Aldrich), 
5 µg/ml insulin (I9278; Sigma-Aldrich), GlutaMAX (35050-079; Gibco) and Penicilin-
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Streptamycin (15140-122; Gibco)).  The suspension was centrifuged at 1500 rpm to remove 
adipocytes, and the pellet was treated with 2U/u L DNase (D4263; Sigma-Aldrich) to 
separate out organoids. Single cells were removed using four quick spins at 1500 rpm, and 
the solution was enriched for organoids. Organoids were embedded in collagen I gels at 
a density of 1-2 organoids/µl and plated as 100-µl suspensions in 24-well (662892; Greiner 
Bio-One) or 8-well (154534; Lab Tek) coverslip-bottomed plates over a 37°C heating block. 
Gels were allowed to polymerize for 30 min at 37°C and then cultured in human tumor 
mammary epithelial medium: 100ml DMEM with 4500 mg/L glucose, sodium pyruvate, 
and sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell 
culture (D6546 Sigma; 1 mL of 100X GlutaMAX (35050-061 Life Technologies); 100 U/ml / 
100ug/ml Pen-Strep (1ml of Pen 10,000 U/ml/ Strep 10,000 ug/ml) (P4333 Sigma); 10 mM 
Hepes Buffer, pH 7.3 (1ml of 1M stock) (118-089-721 Quality Biological, INC.); 0.075% BSA 
(250ul of 30% stock) (A9576 Sigma); 10 ng/ml Cholera Toxin (1ul of 1mg/ml stock) (C8052 
Sigma); 0.47 ug/ml Hydrocortisone (1ml of 50ug/ml stock in PBS) (H0396 Sigma); 5 ug/ml 
Insulin solution, human (125ul of 4mg/ml stock or 50 uL of 10mg/mL stock) (I9278 Sigma); 
5 ng/ml EGF (5ul of 100ug/ml stock) (E9644 Sigma) for six days. 
Preparation of Collagen Gels for Culturing Tumor Organoids 
Tumor organoids isolated from primary human breast tumors were embedded in collagen 
solution prepared from rat tail collagen I (354236; Corning) using the following recipe. 
Combine 375uL of 10X DMEM (D2429; Sigma) and 100uL of NaOH (S2770; Sigma) and 
mix well until the solution turns to a dark pink color. Add 3.5mL of collagen I and mix 
well until the color remains stable. As the pH changes from acidic to neutral to basic, the 
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solution changes color from yellow to light pink/ orange to dark pink. The solution was titrated 
with small volumes of NaOH until the desired color of light pink or salmon was attained. 
All steps were performed on ice. Allow this solution to polymerize on ice for 1-2 hours 
until the solution turns cloudy.  
Culturing Human Tumor Organoids with Serum Autoantibodies 
Tumor organoids collected on day 0 (day of plating them in culture) were fixed in 4% 
paraformaldehyde solution for 15 minutes. The remaining organoids were allowed to 
grow in culture medium with or without 10% of a specific autoantibody* (225uL of culture 
medium + 25uL of autoantibody) for 6 days, or until the organoids were invasive into the 
surrounding collagen I gels.  These gels were then fixed in 4% paraformaldehyde solution 
for 15 minutes and analyzed for their levels of invasion. (* - variations of this experiment 
were also performed at 4% culture volume, and at a constant autoantibody concentration 
of 150ug/mL or 1uM.) 
Immunofluorescence 
Tumors organoids in collagen I gels were harvested at day 6 of culture and fixed for 15 
minutes in 4% paraformaldehyde. They were then embedded in Tissue Tek® Optimal 
Cutting Temperature compound (O.C.T., Sakura) and frozen at -80°C overnight. O.C.T 
blocks were sectioned at 50 micron thickness using a Leica cryostat (Leica Biosystems, 
Germany) set to -27°C. For antibody staining, the O.C.T was removed by rinsing with PBS 
for 45 minutes. Samples were blocked for 2 hours with 10%FBS/1%BSA/PBS solution, 
incubated with the serum autoantibodies (50ug/ml) diluted in a 1%FBS/1%BSA/PBS 
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solution overnight at 4°C. Samples were rinsed with PBS for 30 minutes. Slides were 
incubated with goat anti-human secondary antibody (A-11013; Life Technologies) diluted 
at a 1:200 ratio in a 1%FBS/1%BSA/PBS solution for three hours. Samples were rinsed with 
PBS for 30 minutes, mounted with Fluoromount (F4680; Sigma), and sealed with 
coverslips.  
DIC Microscopy 
Differential interference contrast (DIC) imaging of tumor organoids was conducted 
using an an LD Plan-Neofluar 20×/0.4 Korr Ph2 objective lens and a Cell Observer 
system with a Zeiss AxioObserver Z1 and a AxioCam MRM camera (Carl Zeiss, 
Germany). Photoshop CS6 and ImageJ were used as needed to adjust levels and gamma 
for each channel on entire images to maximize image clarity. 
Confocal Microscopy 
Confocal imaging of fixed tumor sections was conducted with a Zeiss 780 laser scanning 
confocal microscope (Carl Zeiss, Germany). A 40× LD LCI C-Apochromat objective lens 
(Carl Zeiss) was used for high magnification image acquisition with water used as the 
imaging medium. Acquisition of fixed images was performed using Zen 2011.  
Scoring Criteria for Invasion and K14 Intensity 
Invasion Scoring: Score b: The organoid cannot be evaluated or not an organoid. Score d: 
The organoid contains only cells that are rounded up. If there are small clusters, the 
organoid is not dead. Score 0: Organoid has rounded borders. Score 1: Organoid has at 
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least one protrusive cell or a wide front with no clear leaders or has an invasive strand but 
the tip is out of focus. Score 2: Organoid has two or fewer invasive strands (defined as 
containing at least 4 cells in the strand, even if the tip of the strand is blunt). Score 3: 
Organoid has three or more large invasive strands.  
K14 intensity scoring: Score 0: Organoid is negative for K14. Score 1: Organoid has a weak 
diffuse staining or less than 5% focal K14 positive cells. Score 2: Organoid has bright 
diffused staining or greater than 50% of its surface that is K14 positive. Score 3: Organoid 














CHAPTER 3: RESULTS 
3.1 An Ex-Vivo 3D Culture System for Monitoring Invasion of Human Tumor 
Organoids 
Breast cancers use several mechanisms to invade into surrounding tissues, yet our 
understanding of the spectrum of invasive behaviors in human breast tumors is limited. 
Based on a 3D organoid assay previously developed (Cheung et al., 2013), we identified 
K14 positive leader cells participating in the process of collective invasion in tumors from 
mice models of metastatic breast cancer. We have now successfully developed and 
optimized an efficient protocol for isolating tumor organoids from typically 0.2g of tumor 
sample obtained at the time of patient surgery (Fig 1A, B).  
We processed 70 human breast tumors (received from the Cooperative Human Tissue 
Network), and retrieved organoids from 57 of these tumor samples (81% success rate).  
The protocol is now optimized to isolate a median of 1,333 organoids per gram of tissue 
received. These tumor organoids were embedded in collagen I gels to allow us to quantify 
their invasive behavior and to define the molecular phenotype of leader cells. When 
embedded in a collagen matrix, tumor organoids invade and extend several multicellular 
invasive strands (Fig 1C) (Nguyen-Ngoc et al., 2012). The leader cells of such invasive 
strands are positive for K14, a basal epithelial marker (Cheung et al., 2013). 
In this cohort of 70 tumors, only ~30% of tumors invaded efficiently into fibrillar collagen, 
while the others failed to invade despite robust growth in culture (Fig 1D). Consistent 
with data from murine tumors, the cells leading the invasion front were K14+ for more 
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than 95% of leaders identified (Fig 1E).  We scored the level of invasion for 1,981 organoids 
from 58 patient samples on a scale of 0, 1, 2, or 3 (Fig C).  Similarly, we also scored 1,505 
organoids isolated from 56 patient samples for K14 expression intensity on a scale of 0, 1, 
2 or 3. We observed that the invasion efficiency of an organoid was strongly correlated 
with both the level of K14 expression (Fig 1F; n=911 organoids, 53 tumors, p value < 2.2x10-
16) and induction of K14 expression in tumor cells (Fig 1G; n=45 patient samples, R-
correlation = 0.795, p value = 6.52x10-11).  
Apart from these tumor samples, we also received 11 normal mammary specimens from 
breast reduction surgeries. The tissue was processed in a manner similar to the tumors, 
and we were successful in isolating organoids from 73% of these samples. The mean 
isolation rate for normal mammary was 216 organoids per gram of tissue.   
To summarize, we have successfully optimized a protocol for efficient isolation of tumor 
organoids from human breast tumors. We also reveal the spectrum of invasive behavior 
in patient-derived breast tumor samples, and validate that the K14 program is a common 








3.2 Serum Autoantibodies Show Specificity for Mammary Tumor Antigens 
We obtained purified IgGs from the sera of patients with lupus erythematosus, myositis, 
and scleroderma. Organoids generated from human breast tumors were fixed on day 6 of 
culture, and stained with the eighteen autoantibodies provided by the Rosen Lab. As a 
control, we also stained tumor tissue with antisera collected from two normal patients 
(Fig 2A).  
We observed positive staining in ten of the eighteen autoantibodies (56%) we tested 
against tumor tissue (Fig 2B, C). Of these, 100% (10/10) of the autoantibodies stained the 
cytoplasm of tumor cells and 50% (5/10) exhibited positive nuclear staining (Fig 2C). 
Among the different diseases, 75%, 60% and 44% of the dermatomyositis, lupus and 
scleroderma antisera stained tumor organoids (Fig 2B). In order to test if the 
autoantibodies specifically bind only to tumor antigens, we also compared these results 
with those obtained by staining organoids generated from normal mammary reduction 
tissue. In this case, we observed staining with seventeen of these autoantibodies (95%). It 
was surprising to detect binding of patient derived autoantibodies on normal mammary. 
94.1% (16/17) of antisera which showed positive staining stained the cytoplasm and 47.1% 
(8/17) stained the nucleus (Fig 2C). Interestingly, while control antisera failed to stain the 
tumor tissue, they stained the normal mammary tissue. 
We also scored the presence and intensity of staining as – or +, and + or ++ respectively 
(Fig 2C). We observed either cytoplasmic, nuclear or both cytoplasmic and nuclear 
staining with each antiserum (Fig 3A, B). While six antisera stain the normal and tumor 
 
30 
tissues with equal intensities, ten stain normal tissue better.  Two other antisera (13200 
and 12106) show a stronger binding to tumor organoids relative to those obtained from 
normal tissues (Fig 3A, B). This represents an interesting circumstance wherein the 
antibody could be binding to antigens expressed specifically by tumor cells.  
Given the increased binding of autoantibodies to normal tissue, we asked if we were 
detecting immunoglobulin subtypes other than IgG. To test this, we used a secondary 
antibody specific to the Fc receptor of IgG and tested the ability of five control 
autoantibodies (isolated from healthy individuals) to bind organoids derived from a 
single normal mammary reduction tissue. Interestingly, binding patterns of 
autoantibodies did not alter significantly between IgG specific and non-specific secondary 
antibodies, suggesting that the detected signal was from IgGs (Fig 4). 
Six autoantibodies (12106, 13040, 13142, 13200, SLE1269, and FW1366) among the panel of 
eighteen patient-derived autoantibodies showed significant binding against tumor 
antigens. We tested the reproducibility of the staining pattern of these autoantibodies 
against organoids generated from two other human mammary tumors. Tumor #1 was an 
ER+/PR+/HER2- with an invasive ductal histology, tumor #2 was a triple negative lobular 
carcinoma, and tumor #3 was an ER+/PR+/HER2- tumor with both invasive ductal and 
lobular characteristics. The staining pattern of the six autoantibodies varied significantly 
between each of these tumors. The differences were both in terms of signal intensity and 
localization (nuclear vs cytoplasmic or both) (Fig 5). 
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To further assess the ability of autoantibodies to regulate tumor growth, we obtained 
purified IgG from patients with autoimmune disease and a known cancer status. These 
IgGs were also paired for identical known autoantibodies to allow for easier comparison. 
10015 and 9070 contained anti-TIF1 gamma antibodies, the former had no cancer, while 
the latter developed cancer. Similarly, 9109 and 7107 were anti-NXP2 containing sera from 
individuals who had no cancer and cancer respectively. We tested the ability of these 
autoantibodies to bind organoids generated from three human breast tumors – two 
ER+/PR+/HER2- tumors and one triple negative (ER-/PR-/HER2-) tumor. Overall, there 
seems to be no obvious trend differentiating staining patterns between cancer and no 
cancer autoantibodies. One anti-TIF1g autoantibody from a patient with cancer (9070), 
however, seemed to stain the nucleus, while the same autoantibody from a no cancer 
patient (10015) did not show nuclear staining (2/3 tumors) (Fig 6). 
In conclusion, we present the first evidence that autoantibodies from patients with 









3.3 Serum Autoantibodies Regulate Tumor Invasion in 3D Organotypic Cultures 
We next asked if autoantibodies derived from patient sera could affect tumor progression 
in a 3D organotypic culture system. To address this question, we cultured organoids 
derived from human tumors along with autoantibodies. We selected four autoantibodies 
that gave interesting staining patterns with previous experiments – SLE1269, FW1366, 
13200 and 12106. Each autoantibody was added at a concentration of 10% of the total 
culture volume.  
We began by estimating the cytotoxicity of these antibodies to tumor organoids. A dying 
organoid loses its smooth borders and individual cells start rounding up. Based on this 
change in morphology, we assessed the cytotoxicity of each autoantibody. The control 
antibodies showed no cytotoxicity, while patient-derived antibodies caused minimal (4-
17%) cell death (Fig 7B, C).  
We next evaluated the effect of serum autoantibodies on tumor invasion. The tumor 
organoids generated from two primary breast tumors (both ER+/PR+/HER2-) were not 
invasive on day 0 (or the day of plating organoids in culture), but became invasive at day 
6 of culture (Fig 7A). The baseline level of invasion of the two tumors in the absence of 
autoantibodies was 33.3% (9/27 of the organoids analyzed) and 8.3% (2/24 of the organoids 
analyzed) respectively (Fig 7C). Interestingly, in the presence of antibodies isolated from 
no disease controls (C3 and C34), invasion of organoids increased to 56.3% and 41.2% 
respectively for tumor #1 and 30% and 25% respectively for tumor #2  (Fig 7A, C). The 
patient-derived autoantibodies FW1366 increased tumor invasion to 57.1% for tumor #1 
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and 31.6% for tumor #2 (Fig 7A, C, D). Autoantibodies 13200 and 12106, on the other hand, 
decreased invasion in both tumors to 12.5% and 26.1% respectively for tumor #1 and 8.7% 
and 7.8% respectively for tumor #2 (Fig 7A, C, D). When compared to the no-antibody 
control, 13200 decreased tumor invasion by 77.8% (tumor #1) and 70.1% (tumor #2). 
Similarly, 12106 decreased invasion by 53.6% and 60.8% in tumors #1 and #2 respectively. 
Interestingly, both 13200 and 12106 were the autoantibodies that stained tumor organoids 
better than normal organoids. Purified IgG SLE1269 increased baseline invasion of tumor 
#1 to 55%, but decreased the baseline invasion of tumor #2 to 5.9% (Fig 7A, C, D). 
We asked if the ability of autoantibodies to block invasion was dose dependent. We 
cultured organoids isolated from tumor #2 with a lower dosage (4% culture volume) of 
13200 and 12106. The functional effects of the autoantibodies 13200 and 12106 are 
definitely dose dependent, with the lower dosages decreasing invasion by 56.5% and 
44.4% respectively (Fig 7E). However, even this lower dose was sufficient to reduce tumor 
invasion compared to control autoantibodies.  
In summary, autoantibodies alter tumor invasion in 3D organotypic cultures - some 







3.4 Autoantibodies from No Cancer Patients Reduce Tumor Invasion More Effectively 
Than Their Cancer Counterparts 
We next asked if the effect of serum autoantibodies on tumor invasion was dependent on 
the cancer status of the patient. Since the cancer statuses of patients from whom the 
previous set of autoantibodies were collected was unknown, we used purified IgGs 10015 
(anti-TIF1g, no cancer), 9070 (anti-TIF1g, cancer), 7107 (anti-NXP2, no cancer), and 9109 
(anti-NXP2, cancer) for this purpose.  
The tumor (#3) used for this set of experiments was a ER+/PR+/HER2- breast tumor whose 
organoids were 20% invasive in the absence of any autoantibodies (Fig 8B). When cultured 
with 150ug/mL of control antibody C34, the invasion levels remained almost unchanged 
at 20.5% (Fig 8B, C). However, patient derived autoantibodies added at the same 
concentration altered tumor invasion in 3D culture. Antibodies derived from patients 
with cancer – 7107 (anti-NXP2) and 9070 (anti TIF1g) – increased tumor invasion to 20.9% 
and 25% respectively. On the other hand, IgGs isolated from autoimmune patients with 
no cancer – 9109 (anti-NXP2) and 10015 (anti TIF1g) – decreased tumor invasion to 12.1% 
and 18.4% respectively. All of the above autoantibodies had minimal cytotoxicity, ranging 
from 2-10% (Fig 8B, C).  
In conclusion, autoantibodies isolated from patients with no cancer are more effective in 




CHAPTER 4: DISCUSSION AND FUTURE PERSPECTIVES 
Despite the progress in our understanding of breast cancer development and progression, 
patients with metastatic breast cancer continue to have a five-year survival rate of 20%. 
Thus, there is an urgent need to better understand and treat metastasis. Cancer 
immunotherapy is gaining attention for its potential to turn our own immune system 
against cancer. However, drugs against cancer proteins within cells have not been 
developed because antibodies are considered too large to pass through the membrane of 
most cell types. Our research group has previously identified specialized cancer cells that 
commonly lead collective invasion in breast cancers (Cheung et al., 2013). These leader 
cells express keratin-14 (K14) and disrupting K14 expression potently blocks cancer 
invasion and metastasis. These studies indicate that targeting K14 might have therapeutic 
benefit. However, K14 is an intracellular cytoskeletal protein, raising the question how 
K14 might be targeted.  
Autoantibodies are antibodies directed at self-antigens, typically in the context of 
autoimmune disease. An increase in the levels of autoantibodies precedes cancer 
development. Specific autoantibodies in scleroderma patients has been shown to be 
associated with an increased risk for cancer development (Shah et al., 2010), and in a 
subset of these patients, these autoantibodies recognize a somatically mutated gene 
expressed in the breast tumor (Joseph et al., 2014).  Interestingly, lupus auto-antibodies 
against dsDNA have been shown to directly penetrate and kill cells (Hansen et al., 2012). 
This allows for development of drugs that travel through the bloodstream and specifically 
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target cells with certain intracellular proteins. Furthermore, recent unpublished data 
indicates that autoantibodies against K14, a gene important for collective tumor invasion, 
have been identified in the serum of patients with the autoimmune disease 
dermatomyositis. Here we test the hypothesis that autoantibodies from patients with 
autoimmune diseases regulate collective tumor invasion in 3D organotypic cultures. 
Human tumor organoids have emerged as a powerful model for cancer biology. Although 
human tumor organoids offer unique opportunities for experimental therapeutics and 
personalized medicine, it remains unclear how to optimally isolate and analyze tumor 
organoids from patient samples obtained during routine clinical workflow. In this thesis, 
we report our experience developing an efficient methodology that allows us to move 
from patient samples to human tumor organoids to ex-vivo functional readouts for 
invasion. Using this framework, we uncover an unappreciated diversity of invasive 
behavior in human breast tumor samples. It is still unclear how invasion in collagen and 
K14 expression correlates with the survival and relapse information from these patients.  
We then tested eighteen antisera obtained from patients with myositis, lupus and 
scleroderma, and two control antisera from normal patients, for their ability to specifically 
bind tumor cells in organoids generated from human mammary tumors. We showed 
positive cytoplasmic and/or nuclear binding of ten antisera to tumor organoids. Nuclear 
staining was always observed only in a fraction of the cells of the organoid. This is 
consistent with the expected heterogeneity in the tumor cells. Although control antisera 
did not bind tumor organoids, there was significant binding of these antisera with normal 
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mammary organoids. The finding that the level of IgG anti-mammary antibodies is high 
for control sera suggests that these are natural autoantibodies, rather than disease-specific 
autoantibodies. It is possible that the circulation of these normal antibodies is reduced in 
patients with autoimmune diseases. A similar result was found for patients with a chronic 
pulmonary disorder (Daffa et al., 2015). The above binding pattern could also be explained 
by reports suggesting that IgM autoantibodies in the sera of normal individuals reduce 
the reactivity of IgG autoantibodies, and this inhibition is removed when IgG is purified 
from these sera (Melero et al., 1997).  
Two of these antisera we tested – 13200 and 12106 – were from patients with 
dermatomyositis and show higher specificity for tumor cells relative to normal mammary. 
The remaining antisera stain normal breast organoids better than the tumor; this could be 
because cancer cells commonly adopt several strategies to evade the immune recognition, 
and hence could fail to bind these autoantibodies.  
In certain cases, multiple purified IgGs contained the same known antibodies, however, 
their staining pattern was not similar. Since the antibodies are not purified, the observed 
staining pattern could be because of the other antibodies in the serum.  These ‘different’ 
antibodies could possess functional potential in blocking tumor progression.  
The presence of certain autoantibodies in breast cancer patients have been associated with 
a better prognosis (Blixt et al., 2011), implicating a direct role of these autoantibodies in 
preventing tumor progression. Importantly, we have now shown that several serum 
autoantibodies reduce tumor invasion in 3D organotypic culture. IgG purified from 
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normal individuals increases the base line invasion compared to a no antibody control. 
Purified IgGs 13200 and 12106 function in a dose dependent fashion to reduce tumor 
invasion. Another autoantibody – SLE1269 – robustly increases invasion in one tumor, but 
decreases invasion effectively in the other. Since it has been shown that autoantibodies 
can be produced against antigens mutated in the tumor (Joseph et al., 2014), 
autoantibodies in SLE1269 could have been specific to antigens on one of the two tumors. 
The targets of these three IgGs may provide therapeutic targets for breast cancer. The 
nature of the functionally relevant autoantibodies from these sera that block tumor 
invasion could be established by cloning the B-cell receptor from blood cells collected 
from these patients, and testing the effect each clone on collective invasion in 3D 
organotypic cultures. Once we have a specific antibody of interest, we could evaluate its 
in vivo effects on tumor progression by using a human xenograft mouse model.  
About 83% of patients with dermatomyositis that also develop cancer secrete 
autoantibodies against NXP2 and TIF1gamma (Fiorentino et al., 2013). We wanted to test 
if these autoantibodies were any different from the remaining 17% of patients in whom 
malignancy did not present itself. Interestingly, we observed that antibodies from no-
cancer individuals is more effective in reducing tumor invasion than those obtained from 
cancer patients. This further implicates the role of the immune system in keeping cancer 
at bay. As hypothesized by Joseph et al. (Joseph et al., 2014), we believe that in 
autoimmune patients with no cancer, the immune system is actively editing the cancer 
and preventing its emergence.  
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Although it is now known that serum autoantibodies from patients with autoimmune 
diseases holds potential in preventing tumor progression, future efforts should be made 
to elucidate the molecular mechanisms by which this could be achieved. There are several 
studies that prove that serum autoantibodies can physically enter the cells and induce cell 
death (Hansen et al., 2012; Noble et al., 2014). It is worth testing if autoantibodies used in 
this study interfere with collective invasion by cell penetration. This could be 
accomplished by staining fixed tumor organoids treated with autoantibodies with goat 
anti- human secondary antibodies (Golan et al., 1993). 
Development of tumor-selective therapies is a critical goal in cancer research. It has been 
shown that lupus autoantibodies can induce apoptosis in BRCA-deficient tumor cells 
(Hansen et al., 2012) and can sensitize certain cancer cells to anti-cancer drugs (Noble et 
al., 2014). It would also be interesting to see the effect of these selected autoantibodies on 
tumor invasion in the presence of an external anti-cancer therapy. Also, ex-vivo cultures 
described above were carried out with almost no stromal cells. How immune cells alter 
the effect of these antibodies still remains to be understood.  
Since death due to breast cancer is, for the majority, restricted in patients with metastatic 
disease, it is important to develop therapeutic strategies that target this progression. 
Mutations in tumor antigens result in the production of antigenically distinct regions of 
the protein and are able to induce IgG autoantibodies. Several of these antibodies are 
useful in the detection of breast cancer months before the onset of clinical symptoms 
(Madrid and Maroun, 2011). Furthermore, the lower incidence of metastases and delay in 
 
40 
development of metastases in patients with high levels of autoantibodies suggests that the 
antibodies may play a role in inhibiting the progression of malignancy (Blixt et al., 2011). 
The goal of this thesis was to establish the functional potential for autoantibodies derived 
from patients with autoimmune disease to block tumor invasion in 3D culture. Novel 
results presented here suggest that autoantibodies could play a crucial role in controlling 
tumor progression by targeting genes that are critical to collective invasion (Fig 8). These 
experiments also reveal the potential for organoid assays to be used as a mechanism to 
identify therapeutic antibodies that target cancer. The precise mechanism by which this is 





Fig 1: (A) Workflow for isolation of tumor organoids from fresh patient samples. (B) Workflow of 
human tumor organoid generation with pictures taken during the experiment (C) Primary human 
tumor organoids were scored for invasive morphology into four categories. (D) Invasive 
morphology was scored on viable patient samples (N=30 patient samples;  N=1139 organoids) and 
sorted from the least to most invasion. (E) Left panel: DIC image of a collectively invading strand 
of a tumor organoid into Collagen I. Right panel: Confocal image displaying the K14 expression in 
leader cells at the invasive front. (F) Strong positive correlation between the level of invasion and 
K14 expression in the organoids. (G) Strong positive correlation between the level of invasion and 




Fig 2: (A) Schematic for immunofluorescence staining. Control 1: Staining with control antisera 
from normal patients, Control 2: Staining normal mammary organoids with all antisera. (B)  
Distribution of the total number of autoantibodies among the various disease types, and fraction of 
positive staining with normal breast and tumor organoids. (C) List of all antisera, disease type, 
known antibodies for each, and positivity of staining in the cytoplasm and nucleus against tumor 




Fig 3: (A) Representative images of staining results for two control antisera (C19, LCR) and 
eighteen patient antisera used to stain patient breast tumor organoids. Images are arranged in 
decreasing order of intensity. (B) Representative images of staining results for two control antisera 
(C19, LCR) and eighteen patient antisera used to stain normal breast organoids. Images are order 
matched to the panel above.  
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Fig 4: Representative images of normal mammary organoids stained with control autoantibodies 
(LCR, C19, C3, C17 and C34). Staining procedures were completed with one of two secondary 





Fig 5: Representative images of tumor organoids generated from three human breast tumors stained 




Fig 6: Representative images of tumor organoids generated from three human breast tumors stained 
with patient derived autoantibodies. 10095 and 9070 are autoantibodies directed against TIF1 
gamma purified from the serum of patients without or with cancer respectively. Similarly, anti-





Fig 7: (A) Effect of autoantibodies on tumor invasion in 3D organotypic culture. Representative 
DIC images depicting the invasion profile of tumor organoids collected on d0, or d6 without any 
autoantibody, or d6 with one of the following autoantibodies – SLE1269, FW1366, 13200, 12106, 
C33 or C34 (control autoantibodies). (B) Bar graph comparing the cytotoxicity of each 
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autoantibody. (C) Table summarizing the cytotoxicity, percentage invasion and percentage 
decrease in invasion for each autoantibody (n=2 tumors). (D) Bar graph comparing the effect of 
each autoantibody on collective invasion of tumor organoids derived from 2 tumors. (E) Dose-





Fig 8: Effect of patient cancer-status on autoantibody-mediated decrease in tumor invasion. (A) 
Representative DIC images depicting the invasion profile of tumor organoids collected on d0, or d6 
without any autoantibody, or d6 with one of the following autoantibodies – 7107, 9070, 9109, 
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10015 or C34 (control autoantibody). (B) Table summarizing the invasion score, percentage 
invasion and cytotoxicity for each autoantibody (n=1 tumor). (C) Bar graph comparing the effect 
















Fig 9: Working model - Autoantibodies derived from patients with autoimmune diseases (AutoAbs) 
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